Articles related to DIABETIC EYE DISEASE (DED)

Diabetic retinopathy is the only leading cause of blindness that has not experienced a decrease in age-standardized prevalence between 1990 and 2020, highlighting the urgent need for improved prevention and management strategies.

Autonomous AI at the point of care significantly increases diabetic retinopathy screening rates among young patients, addressing access gaps in underserved communities and offering a practical solution to improve patient outcomes.

In a significant advance for pediatric diabetes care, the introduction of the AI-based IDx-DR has doubled screening rates for diabetic retinopathy, underscoring the potential of technology to democratize healthcare access and eliminate racial bias in diagnostic processes.

This study provides compelling evidence that diabetes significantly alters the circadian rhythm of the transcriptomic profile in retinas. Such findings underscore the need for further research into this area, particularly given that diabetic retinopathy is a prevalent complication of diabetes.

Explore how an eyecare practice scaled its services for diabetic patients, achieving a 5% growth in this segment and setting a model for patient-centered, profitable care.

An experimental drug called 32-134D shows promise in preventing or slowing vision loss in individuals with diabetes, according to a study conducted by researchers at the Wilmer Eye Institute, Johns Hopkins Medicine. The study, which utilized mouse models, human retinal organoids, and eye cell lines, focused on proliferative diabetic retinopathy and diabetic macular edema. The findings, published in the Journal of Clinical Investigation, indicate that 32-134D reduced levels of a protein called HIF, which is responsible for diabetic retinal vascular disease. The drug was found to be safer than another HIF-targeting treatment under investigation. Dr. Akrit Sodhi, the author of the study, emphasizes the drug’s well-tolerated nature and its ability to effectively reduce HIF levels in diseased eyes. Elevated levels of HIF in the eyes lead to increased blood vessel production and leakage in the retina, contributing to vision loss. The researchers tested 32-134D on human retinal cell lines and observed a return to near-normal gene expression levels, halting the creation of new blood vessels and maintaining vascular integrity. The drug was also tested on mouse models, resulting in diminished HIF levels and inhibition of new blood vessel formation and leakage. Remarkably, the drug exhibited active levels in the retina […]